New blood tests designed to identify Alzheimer’s disease years before symptoms appear have sparked considerable interest, but medical experts caution that these tools are not yet ready for broad use, particularly among individuals without cognitive symptoms. The U.S. Food and Drug Administration has approved four blood tests intended to help clinicians determine whether Alzheimer’s is the cause of memory problems or other cognitive impairments, distinguishing it from other types of dementia or medical conditions. However, specialists emphasize that these tests are currently recommended only for patients exhibiting symptoms.

While some laboratories and private services offer Alzheimer’s-related blood testing directly to consumers, dementia experts warn against their use by the “worried well”—those who have no cognitive complaints. Nicholas Ashton, a testing expert at Banner Health in Arizona, advises that such tests should be limited to research settings for people without symptoms. A positive test largely indicates a risk factor rather than a definitive diagnosis. For example, many older adults have elevated amyloid levels, a hallmark of Alzheimer’s, but never develop cognitive decline. Conversely, a negative result provides more reliable reassurance that Alzheimer’s pathology is absent.

A recent study led by researchers at Mass General Brigham found that older adults with markedly elevated p-tau217—a protein linked to Alzheimer’s—had about a 38% chance of developing cognitive impairment within five years, with risk increasing over a decade. Yet such findings underscore the complexity and uncertainty of predicting individual outcomes based solely on biomarkers.

While awaiting more definitive clinical applications of these blood tests, experts underscore the importance of lifestyle and health management to reduce dementia risk. A large trial conducted last year demonstrated that adopting healthier habits significantly slowed age-related cognitive decline in individuals at higher risk. Recommended measures include engaging in at least 30 minutes of moderate exercise four times weekly, participating in resistance training twice a week, and adhering to the MIND diet, which emphasizes leafy greens, berries, whole grains, poultry, and fish. Additional advice from dementia specialists includes ensuring adequate sleep, avoiding social isolation, addressing hearing loss, and stimulating the brain through mental activities.

Middle age presents a crucial window for preventive action. A long-term study of more than 12,000 individuals tracked from an average age of 56 revealed that managing cardiovascular risks—such as controlling high blood pressure, treatment of type 2 diabetes, and avoiding smoking—correlates with better cognitive health in later life. Even carriers of the APOE4 gene, a known genetic risk factor for Alzheimer’s, showed cognitive benefits from maintaining healthier lifestyles during middle age.

Experts also highlight the importance of early and sustained treatment of high blood pressure to protect brain health. “Be very serious with your physician about the value of lowering it as early as possible for as many years as possible,” urged epidemiologist Elizabeth Coresh, who led the research.

Ongoing clinical trials are investigating whether current Alzheimer’s medications might effectively delay or prevent the onset of symptoms in people identified as high risk. These developments could eventually reshape the role and timing of blood-based Alzheimer’s testing. For now, the focus remains on managing known risk factors and monitoring for symptoms rather than widespread preemptive screening.